Kura Other Stockholder Equity vs Non Currrent Assets Other Analysis
KURA Stock | USD 22.17 0.81 3.52% |
Kura Oncology financial indicator trend analysis is infinitely more than just investigating Kura Oncology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kura Oncology is a good investment. Please check the relationship between Kura Oncology Other Stockholder Equity and its Non Currrent Assets Other accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.
Other Stockholder Equity vs Non Currrent Assets Other
Other Stockholder Equity vs Non Currrent Assets Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kura Oncology Other Stockholder Equity account and Non Currrent Assets Other. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Kura Oncology's Other Stockholder Equity and Non Currrent Assets Other is 0.89. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Kura Oncology, assuming nothing else is changed. The correlation between historical values of Kura Oncology's Other Stockholder Equity and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Kura Oncology are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Other Stockholder Equity i.e., Kura Oncology's Other Stockholder Equity and Non Currrent Assets Other go up and down completely randomly.
Correlation Coefficient | 0.89 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Other Stockholder Equity
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Most indicators from Kura Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kura Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.At present, Kura Oncology's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 155.6 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (6.57).
Kura Oncology fundamental ratios Correlations
Click cells to compare fundamentals
Kura Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kura Oncology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 242.0M | 647.2M | 534.1M | 456.3M | 448.9M | 471.4M | |
Total Stockholder Equity | (212.9M) | (302.5M) | (433.0M) | (568.8M) | 397.3M | 417.1M | |
Net Debt | (18.6M) | (310.5M) | (83.8M) | (37.8M) | (20.1M) | (21.1M) | |
Retained Earnings | (212.9M) | (302.5M) | (433.0M) | (568.8M) | (721.4M) | (685.4M) | |
Cash | 26.1M | 325.5M | 90.7M | 51.8M | 37.3M | 40.2M | |
Cash And Short Term Investments | 236.9M | 633.3M | 518.0M | 438.0M | 424.0M | 445.2M | |
Liabilities And Stockholders Equity | (189.7M) | (266.2M) | (405.5M) | (532.8M) | 448.9M | 471.4M | |
Other Stockholder Equity | (336K) | (53K) | 1.8M | 8.0M | 1.1B | 1.2B | |
Total Current Assets | 239.6M | 637.3M | 522.3M | 446.4M | 432.5M | 454.1M | |
Common Stock | 3K | 4K | 5K | 7K | 8.1K | 6.7K | |
Total Current Liabilities | 15.6M | 26.0M | 22.5M | 24.1M | 35.3M | 37.0M | |
Other Assets | 2.1M | 7.9M | 3.5M | 3.5M | 4.0M | 4.2M | |
Common Stock Shares Outstanding | 41.9M | 53.1M | 66.4M | 67.0M | 73.2M | 76.9M | |
Non Current Liabilities Total | 7.6M | 10.3M | 5.0M | 12.0M | 16.4M | 17.2M | |
Total Liab | 23.2M | 36.3M | 27.4M | 36.0M | 51.7M | 54.2M | |
Other Current Liab | 11.8M | 18.2M | 17.0M | 20.2M | 31.5M | 33.0M | |
Accounts Payable | 3.5M | 2.8M | 3.2M | 1.5M | 2.3M | 1.9M | |
Common Stock Total Equity | 3K | 4K | 5K | 7K | 8.1K | 8.5K | |
Other Current Assets | 2.7M | 4.0M | 4.3M | 8.4M | 5.7M | 6.0M | |
Net Tangible Assets | 218.8M | 610.9M | 506.6M | 420.3M | 483.3M | 507.5M | |
Retained Earnings Total Equity | (212.9M) | (302.5M) | (433.0M) | (568.8M) | (511.9M) | (486.3M) | |
Capital Surpluse | 431.3M | 913.4M | 941.4M | 997.1M | 1.1B | 1.2B | |
Non Current Assets Total | 2.4M | 9.9M | 11.8M | 9.9M | 16.5M | 17.3M | |
Non Currrent Assets Other | 2.3M | 1.4M | 3.3M | 3.3M | 7.4M | 7.8M | |
Other Liab | 377K | 395K | 375K | 265K | 238.5K | 324.6K | |
Long Term Debt | 7.5M | 7.3M | 4.3M | 9.2M | 9.3M | 7.1M | |
Short Term Investments | 210.8M | 307.8M | 427.3M | 386.2M | 386.6M | 237.8M | |
Accumulated Other Comprehensive Income | 331K | 46K | (1.8M) | (8.0M) | (1.3M) | (1.3M) | |
Non Current Liabilities Other | 377K | 6.0M | 5.0M | 265K | 705K | 669.8K | |
Long Term Debt Total | 7.5M | 7.3M | 4.3M | 9.2M | 10.5M | 7.5M | |
Net Invested Capital | 226.3M | 618.2M | 506.6M | 429.4M | 406.6M | 383.8M | |
Net Working Capital | 224.0M | 611.3M | 499.8M | 422.4M | 397.2M | 378.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.17) | Return On Assets (0.23) | Return On Equity (0.37) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.